Drug Search Results
More Filters [+]

Apixaban

Alternative Names: apixaban, eliquis
Latest Update: 2024-12-19
Latest Update Note: Clinical Trial Update

Product Description

Apixaban is used help prevent strokes or blood clots in people who have atrial fibrillation (a condition in which the heart beats irregularly, increasing the chance of clots forming in the body and possibly causing strokes) that is not caused by heart valve disease. Apixaban is also used to prevent deep vein thrombosis (DVT; a blood clot, usually in the leg) and pulmonary embolism (PE; a blood clot in the lung) in people who are having hip replacement or knee replacement surgery. Apixaban is also used to treat DVT and PE and may be continued to prevent DVT and PE from happening again after the initial treatment is completed. Apixaban is in a class of medications called factor Xa inhibitors. It works by blocking the action of a certain natural substance that helps blood clots to form. (Sourced from: https://medlineplus.gov/druginfo/meds/a613032.html)

Mechanisms of Action: VKOR Antagonist,FXa Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Atrial Fibrillation | Embolism | Embolism and Thrombosis | Thrombosis | Stroke | Pulmonary Embolism

Known Adverse Events: Injuries/wounds Unspecified

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Apixaban

Countries in Clinic: Austria, Belgium, Canada, China, France, Germany, Greece, India, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom, United States

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Atrial Fibrillation|Kidney Diseases|Kidney Failure, Chronic|Myelofibrosis|Polycythemia Vera|Thrombocythemia, Essential|Thrombosis

Phase 2: Healthy Volunteers|Heart Failure

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AVAJAK

P3

Active, not recruiting

Thrombocythemia, Essential|Polycythemia Vera|Myelofibrosis

2026-06-03

TAH3311-CP-2301

P2

Not yet recruiting

Healthy Volunteers

2025-01-01

API-CAT

P3

Completed

Thrombosis

2024-09-06

DOAC LVAD

P2

Completed

Heart Failure

2023-10-05

Recent News Events